Coccidioidomycosis in Patients Treated With Ruxolitinib
- PMID: 32548203
- PMCID: PMC7284005
- DOI: 10.1093/ofid/ofaa167
Coccidioidomycosis in Patients Treated With Ruxolitinib
Abstract
We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.
Keywords: coccidioidomycosis; fungal infections; immunocompromised host; ruxolitinib.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
References
-
- Dioverti MV, Abu Saleh OM, Tande AJ. Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature. Infect Dis (Lond) 2018; 50:381–7. - PubMed
-
- Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 2018; 93:339–47. - PubMed
-
- Blair JE, Ampel NM, Hoover SE. Coccidioidomycosis in selected immunosuppressed hosts. Med Mycol 2019; 57(Suppl 1):S56–63. - PubMed
-
- Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489–94. - PubMed
